EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeted Protein Degradation of the Latency‐Associated Nuclear Antigen Evicts Kaposi Sarcoma‐Associated Herpesvirus Episomes From Infected Cells In Vitro

Sarah McMahon iD, Maha Amer, Brooke Hall, Ritu Shekhar iD, Rolf Renne

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Sarah McMahon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Antigens, Viral, Virus Latency, Nuclear Proteins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposi sarcoma‐associated herpesvirus (KSHV), a gamma‐herpesvirus, is the main etiological agent of several tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). The large, double‐stranded viral genome of KSHV is maintained as a latent episome in the nucleus of host cells, where a small subset of viral genes is expressed that facilitate evasion of immune responses and promotion of cell survival and proliferation supporting tumorigenesis. The major latency‐associated nuclear antigen (LANA) is an essential viral factor that is required for genome replication and segregation to maintain viral genomes within dividing cells. Given the essential role of LANA to maintain viral latency, efforts have focused on targeting LANA's role in replication and segregation as a mechanism to overcome latency and tumorigenesis. However, given the complexity in small molecule targeting to DNA‐binding domains, current efforts focused on drugging LANA continue to reach potency milestones for clinical trials. Here, we developed a HaloTag‐based PROTAC model as a proof‐of‐concept for targeted LANA protein degradation. Our findings highlight the power of a PROTAC‐based strategy on eliminating LANA and viral persistence in tissue culture demonstrating promise in the on‐going challenge for targeting this major viral factor in KSHV latency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 8, HumanAntigens, ViralVirus LatencyNuclear ProteinsPlasmidsHumansProteolysisVirus ReplicationSarcoma, Kaposi

Stichwörter der Autor:innen

Kaposi's sarcoma‐associated herpesvirusLANAPROTACtargeted protein degradationviral latency

Substanzen

latency-associated nuclear antigenAntigens, ViralNuclear Proteins

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA.
  • UF Health Cancer Center, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Sarah McMahon, Ritu Shekhar

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

McMahon, S., Amer, M., Hall, B., Shekhar, R., & Renne, R. (2025). Targeted Protein Degradation of the Latency‐Associated Nuclear Antigen Evicts Kaposi Sarcoma‐Associated Herpesvirus Episomes From Infected Cells In Vitro. Journal of Medical Virology. https://doi.org/10.1002/jmv.70765

Vancouver

McMahon S, Amer M, Hall B, Shekhar R, Renne R. Targeted Protein Degradation of the Latency‐Associated Nuclear Antigen Evicts Kaposi Sarcoma‐Associated Herpesvirus Episomes From Infected Cells In Vitro. Journal of Medical Virology. 2025. doi:10.1002/jmv.70765

BibTeX
@article{McMahon2025,
  author = {McMahon, Sarah and Amer, Maha and Hall, Brooke and Shekhar, Ritu and Renne, Rolf},
  title = {Targeted Protein Degradation of the Latency‐Associated Nuclear Antigen Evicts Kaposi Sarcoma‐Associated Herpesvirus Episomes From Infected Cells In Vitro},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70765}
}
Kostenlos starten →